KR20180031704A - 병용 요법 - Google Patents

병용 요법 Download PDF

Info

Publication number
KR20180031704A
KR20180031704A KR1020187004149A KR20187004149A KR20180031704A KR 20180031704 A KR20180031704 A KR 20180031704A KR 1020187004149 A KR1020187004149 A KR 1020187004149A KR 20187004149 A KR20187004149 A KR 20187004149A KR 20180031704 A KR20180031704 A KR 20180031704A
Authority
KR
South Korea
Prior art keywords
biofilm
polypeptide
combination therapy
serine protease
streptococcus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187004149A
Other languages
English (en)
Korean (ko)
Inventor
아구스타 굿문스도티어
레이니어 쉐빙
Original Assignee
엔지메티카 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔지메티카 에이비 filed Critical 엔지메티카 에이비
Publication of KR20180031704A publication Critical patent/KR20180031704A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
KR1020187004149A 2015-07-24 2016-07-22 병용 요법 Withdrawn KR20180031704A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15178209.1A EP3120866A1 (en) 2015-07-24 2015-07-24 Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
EP15178209.1 2015-07-24
PCT/EP2016/067570 WO2017017027A1 (en) 2015-07-24 2016-07-22 Combination therapies

Publications (1)

Publication Number Publication Date
KR20180031704A true KR20180031704A (ko) 2018-03-28

Family

ID=53785469

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187004149A Withdrawn KR20180031704A (ko) 2015-07-24 2016-07-22 병용 요법

Country Status (12)

Country Link
US (1) US11338021B2 (cg-RX-API-DMAC7.html)
EP (2) EP3120866A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018521143A (cg-RX-API-DMAC7.html)
KR (1) KR20180031704A (cg-RX-API-DMAC7.html)
CN (1) CN107921102B (cg-RX-API-DMAC7.html)
AU (1) AU2016301021B2 (cg-RX-API-DMAC7.html)
CA (1) CA2992677A1 (cg-RX-API-DMAC7.html)
DK (1) DK180380B1 (cg-RX-API-DMAC7.html)
ES (1) ES2989635T3 (cg-RX-API-DMAC7.html)
MX (1) MX2018000984A (cg-RX-API-DMAC7.html)
RU (1) RU2725800C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017017027A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701315D0 (en) 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
WO2020229521A1 (en) * 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
JP7854397B2 (ja) * 2020-05-13 2026-05-01 ジーミキュー テクノロジー アクチエボラグ 微生物感染治療のためのプロテアーゼ製剤
CN119499437A (zh) * 2024-11-27 2025-02-25 武汉大学中南医院 一种负载胰蛋白酶抗细菌生物膜的温敏性水凝胶敷料及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
ATE278417T1 (de) 1999-06-18 2004-10-15 Jon Bragi Bjarnason Pharmazeutische- und kosmetischezusammensetzungen enthaldend serinproteasen aus kabeljau und deren pharmazeutische und kosmetische verwendung
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
US9931381B2 (en) 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
KR102211724B1 (ko) 2011-05-31 2021-02-03 허치슨 바이오필름 메디컬 솔루션스 리미티드 세포 응집물의 분산 및 분리
CN103007258A (zh) 2011-09-22 2013-04-03 安淇生物控释技术(苏州)有限公司 含鱼丝氨酸蛋白酶和抗菌化合物的医用组合物及其用途
RU2014129910A (ru) * 2011-12-21 2016-02-10 Колгейт-Палмолив Компани Композиции для ухода за полостью рта
CN103191491A (zh) 2012-01-10 2013-07-10 查红梅 一种包装物及其用途和制法
RU2646102C2 (ru) 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
KR20150013280A (ko) 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
CN203090136U (zh) * 2013-02-02 2013-07-31 成都玺汇科技有限公司 一种口鼻两用喷雾器
GB201405784D0 (en) * 2014-03-31 2014-05-14 Enzymatica Ab Novel methods, polypeptides and uses thereof
DK3099317T3 (en) * 2014-01-29 2021-08-23 Enzymatica Ab Cod trypsin for use in the treatment of microbial infections in a subject with immunodeficiency

Also Published As

Publication number Publication date
CA2992677A1 (en) 2017-02-02
JP2018521143A (ja) 2018-08-02
US20200085921A1 (en) 2020-03-19
BR112018001391A2 (en) 2018-09-11
MX2018000984A (es) 2018-08-09
US11338021B2 (en) 2022-05-24
DK180380B1 (en) 2021-03-17
WO2017017027A1 (en) 2017-02-02
ES2989635T3 (es) 2024-11-27
EP3325002C0 (en) 2024-09-04
CN107921102A (zh) 2018-04-17
EP3325002B1 (en) 2024-09-04
RU2018106490A3 (cg-RX-API-DMAC7.html) 2020-01-24
EP3120866A1 (en) 2017-01-25
AU2016301021B2 (en) 2022-11-10
RU2018106490A (ru) 2019-08-26
RU2725800C2 (ru) 2020-07-06
AU2016301021A1 (en) 2018-02-01
EP3325002A1 (en) 2018-05-30
DK201870043A1 (en) 2018-02-05
CN107921102B (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
Dostert et al. Design and assessment of anti-biofilm peptides: steps toward clinical application
Visperas et al. Current treatments for biofilm‐associated periprosthetic joint infection and new potential strategies
KR101694930B1 (ko) 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
BR112013015010B1 (pt) produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana
DK180380B1 (en) Combination therapy compositions for use in treating a bacterial biofilm in a subject and methods for killing, inhibiting or preventing the growth of a bacterial biofilm in vitro
JP2018083830A (ja) 細菌性バイオフィルムを除去するためのセアプローゼの使用
WO2018138292A1 (en) A polypeptide having protease activity for use in treating otitis
EP3086805B1 (en) Use of glycyl-glycine endopeptidase for treating mycobacteria infections
US11197824B2 (en) Solution and method for reducing the virulence of viruses, bacteria,yeasts, or fungus
BR112018001391B1 (pt) Uso de uma terapia de combinação compreendendo um polipeptídeo e um ou mais compostos de antibiótico, dispositivo médico para entrega do medicamento, e método para eliminação, inibição ou prevenção do crescimento de um biofilme bacteriano in vitro
EP4048073B1 (en) Fibrinogen as adjuvant for antimicrobial agents and therapy
CA2934670A1 (en) Ultra-low dose lysostaphin for treating mrsa
HK40071837A (en) Fibrinogen as adjuvant for antimicrobial agents and therapy
HK40071837B (en) Fibrinogen as adjuvant for antimicrobial agents and therapy
HK1162586B (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210623

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20230313

WITB Written withdrawal of application